KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Cash (2016 - 2025)

Emergent BioSolutions' Change in Cash history spans 16 years, with the latest figure at -$40.1 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 21.06% year-over-year to -$40.1 million; the TTM value through Dec 2025 reached $103.5 million, up 1796.72%, while the annual FY2025 figure was $103.5 million, 1796.72% up from the prior year.
  • Change in Cash reached -$40.1 million in Q4 2025 per EBS's latest filing, down from -$21.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $401.6 million in Q4 2022 to a low of -$344.2 million in Q2 2023.
  • Average Change in Cash over 5 years is -$20.6 million, with a median of -$36.4 million recorded in 2024.
  • Peak YoY movement for Change in Cash: plummeted 636.5% in 2021, then surged 10775.0% in 2024.
  • A 5-year view of Change in Cash shows it stood at $172.3 million in 2021, then surged by 133.08% to $401.6 million in 2022, then crashed by 94.05% to $23.9 million in 2023, then plummeted by 312.55% to -$50.8 million in 2024, then rose by 21.06% to -$40.1 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Cash are -$40.1 million (Q4 2025), -$21.8 million (Q3 2025), and $118.2 million (Q2 2025).